Recent evidence suggests that cross-talk between the PI3K and MAPK signaling pathways exist. We use pAkt and pERK antibodies to examine the PI3K/MAPK interactions. Additionally, to further interrogate the interplay between these two pathways, cell proliferative marker Ki-67 is used to validate the final biological effect.
Millipore’s FlowCellect™ PI3K/MAPK Dual Activation and Cancer Detection Kit is designed to examine this cross-talk in a multi-parametric fashion by providing three fully validated and optimized antibody biomarkers to measure specific cell signaling events in flow applications. The three antibodies provided in the kit are Anti-phospho-Akt Alexa Fluor 488 conjugate, Anti-phospho-ERK R-Phycoerythrin conjugate, and Anti-Ki-67 PerCP conjugate. By utilizing all three antibody biomarkers simultaneously in flow applications, we now have the ability to thoroughly evaluate the “cross-talk” between PI3K and MAPK pathways and to further determine the consequence of their interplay in cell proliferation and differentiation by measuring their effect on Ki-67 expression.
Phosphorylated Akt and phosphorylated ERK are included in the kit to provide the end user with the means to cross-examine both the PI3K and MAPK signaling pathways simultaneously. It has been suggested that the phosphorylation of Akt can result in the inhibition, or dephosphorylation, of phospho-Raf on Ser 259 [Jun, T. et al. (1999) ]. By inactivating Raf, this will essentially block the MAPK signaling pathway resulting in an inactivated phospho-ERK. In some situations, a surface receptor (such as IGF-1) will activate both the PI3K and MAPK pathways leading to the phosphorylation of both Akt and ERK. However, since this interaction or “cross-talk” exist between the two pathways, it is critical to investigate their interactions in both a spatial and temporal manner.
In a recent study, we have examined the effects of IGF-1 activation by the addition of Insulin on both the PI3K and MAPK signaling pathways on HEK293 cells. We have performed this experiment implementing critical time points for signaling evaluation: activation at 3 minute and at 5 minute time intervals. The resulting responses indicate that cross-talk is observed, noted by a sharp decrease in ERK expression. This transient response is attributed to the phosphorylation of Akt, which in turn will shut off phosphorylated ERK as noted above.
In order to validate the biological effect of phospho-protein activation by a given stimulus, cell cycle marker Ki-67 is used since it is a true measurement of the “proliferative fraction”. Ki-67 is present in all phases of the cell cycle except for G0. However, Ki-67 can only be detected in flow cytometry when cells are going through M phase as Ki-67 expression patterns are punctate in all other phases producing weaker signals. But by using a cell cycle arrest reagent, Cell Cycle Stop™, cell proliferation measured by Ki-67 expression can be accurately determined as cells are arrested at M phase and are clearly visible in flow cytometry analysis. In order to accurately measure the cell proliferative activity by Ki-67 expression, however, cells must be treated for at least 12 hours with a combination of Cell Cycle Stop™ and a given cell stimulus to fully achieve enough circulating cells to be captured in M-phase. Additionally, prior to cell treatments all cultures must be serum starved for 24 hours to essentially reset the cell cycle and bring most circulating cells back to G0 [Littleton, RJ. et al. (1991) ].
Using multi-parametric flow analysis, we are able to cross-examine these signaling events and their biological consequence simultaneously, providing a biological correlation between pathway activation and cancer proliferation.